/
AKBA
$0.87-$0.02 (-2.64%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$247.5M
277M shares
52-week range
$0.82 – $3.34
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-1.56
Akebia Therapeutics, Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
www.akebia.com- Employees
- 194
- IPO / List date
- Mar 20, 2014
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds AKBA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,833,128 | $2.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AKBA yet.
